Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects

Journal of Clinical Psychopharmacology
Ji-Young ParkJae-Gook Shin

Abstract

This study was to evaluate the combined effects of the CYP3A4 inhibitor itraconazole and the CYP2D6*10 genotype on the pharmacokinetics and pharmacodynamics of haloperidol, a substrate of both CYP2D6 and CYP3A4, in healthy subjects. Nineteen healthy volunteers whose CYP2D6 genotypes were predetermined were enrolled (9 for CYP2D6*1/*1 and 10 for CYP2D6*10/*10). Four subjects (1 for CYP2D6*1/*1 and 3 for CYP2D6*10/*10) did not complete the study because of adverse events. The pharmacokinetics of haloperidol and its pharmacodynamic effects measured for QTc prolongation and neurologic side effects were evaluated after a single dose of 5 mg haloperidol following a pretreatment of placebo or itraconazole at 200 mg/d for 10 days in a randomized crossover manner. Itraconazole pretreatment increased the mean area under the time-concentration curves (AUCs) of haloperidol by 55% compared to placebo pretreatment (21.7 +/- 11.3 vs 33.5 +/- 29.3 ng h/mL). The subjects with CYP2D6*10/*10 genotype showed 81% higher AUC compared to that of subjects with CYP2D6*1/*1 genotype (27.6 +/- 22.2 vs 50.2 +/- 47.1 ng h/mL). In the presence of itraconazole, subjects with CYP2D6*10/*10 showed 3-fold higher AUC of haloperidol compared to that of placebo pr...Continue Reading

References

Apr 1, 1992·Therapeutic Drug Monitoring·A LlerenaL Bertilsson
Jun 1, 1992·Journal of Clinical Psychopharmacology·T SomeyaT Inaba
Jan 1, 1991·Human & Experimental Toxicology·R A HendersonJ A Henry
Dec 26, 1991·Biochemical and Biophysical Research Communications·B SubramanyamN Castagnoli
Sep 15, 1990·Biological Psychiatry·D D MillerW H Coryell
Aug 1, 1990·Chest·M KriwiskyY Kishon
May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Dec 1, 1986·Journal of Clinical Psychopharmacology·S A Fayer
Dec 1, 1994·European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)·C P Caygill
Mar 29, 1996·Journal of Chromatography. B, Biomedical Applications·D R JonesS D Hall
Apr 1, 1997·Cellular and Molecular Neurobiology·J FangR T Coutts
Feb 12, 1998·British Journal of Clinical Pharmacology·L P PanF M Belpaire
May 8, 1999·British Journal of Clinical Pharmacology·T FukudaJ Azuma
Jun 9, 1999·The American Journal of Psychiatry·J KornhuberP Riederer
Jan 11, 2000·Clinical Pharmacokinetics·S Kudo, T Ishizaki
Mar 10, 2000·Clinical Pharmacokinetics·K VenkatakrishnanD J Greenblatt
Sep 9, 2000·Clinica Chimica Acta; International Journal of Clinical Chemistry·K IwahashiK Igarashi
Jul 17, 2001·British Journal of Clinical Pharmacology·C SendaK Chiba
Oct 23, 2001·Pharmacogenetics·M Ingelman-Sundberg, W E Evans
Dec 26, 2001·Antimicrobial Agents and Chemotherapy·Er-jia WangWilliam W Johnson
Jan 17, 2002·European Journal of Clinical Pharmacology·H K RohL Bertilsson
May 29, 2002·Life Sciences·David W BoultonJohn S Markowitz
Aug 2, 2002·Clinical Pharmacology and Therapeutics·Andrea GaedigkJ Steven Leeder
Oct 19, 2002·Clinical Pharmacology and Therapeutics·Jürgen BrockmöllerIvar Roots
Apr 15, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Koichi OharaHaruo Shibuya

❮ Previous
Next ❯

Citations

Oct 5, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Xianbin TianKim L R Brouwer
Feb 16, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Xianbin TianKim L R Brouwer
Nov 15, 2006·Antimicrobial Agents and Chemotherapy·Angela Sansone-ParsonsRandall Stoltz
Jan 1, 2008·Journal of Asthma and Allergy·David Axelrod, Leonard Bielory
Nov 12, 2009·Clinical Pharmacokinetics·Shu-Feng Zhou
Dec 21, 2007·Journal of Clinical Pharmacology·Kyoung-Ah KimJi-Young Park
Mar 30, 2016·Pharmacogenomics·Stefano PorcelliDan Rujescu
Jun 26, 2015·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Maartje N NiemeijerBruno H Stricker
Jul 23, 2013·Schizophrenia Research·Dana RavynHenry A Nasrallah
Jun 20, 2008·The Journal of Physical Chemistry. a·Philip R BaldingSam P de Visser
May 6, 2021·CPT: Pharmacometrics & Systems Pharmacology·Camille CouffignalJulie Bertrand

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

© 2022 Meta ULC. All rights reserved